A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Key Inclusion Criteria:

• Provide written, informed consent to participate in the study and follow the studyprocedures
• Karnofsky Performance Status (KPS) of at least 70%
• Measurable disease per mRECIST 1.1 criteria
• Histologically confirmed RCC with a clear-cell component (may have sarcomatoidfeatures); advanced (not amenable to curative surgery or radiation therapy) ormetastatic (AJCC Stage IV) RCC
• Patients with any International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score (favorable-, intermediate-, or poor-risk) are eligible. At least one IMDCprognostic factor must be present to qualify as either intermediate- or poor-riskrenal cell carcinoma.
• No prior systemic therapy (including neoadjuvant, adjuvant, or vaccine therapy) forRCC

Key Exclusion Criteria:

• An active, known or suspected autoimmune disease that has required systemic treatmentwithin the past 3 months (exceptions exist)
• Patients who have a known additional malignancy that is progressing or requires activetreatment (exceptions exist)
• Any tumor invading the wall of a major blood vessels
• Any tumor invading the gastrointestinal (GI) tract or any evidence of endotracheal orendobronchial tumor within 28 days prior to randomization
• Need for >2 medications for management of hypertension (including diuretics)
• History of pulmonary embolism, deep vein thrombosis (not including tumor thrombus), orclinically significant thromboembolic event within 3 months of randomization Additional protocol defined inclusion/exclusion criteria and exceptions apply